Burlingame, CA, United States of America

Theodore Yun

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Janssen Biopharma, Inc.. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Theodore Yun. Retrieved from https://idiyas.com/inventor/theodore-yun

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Theodore Yun in Immunostimulatory Therapies

Introduction

Theodore Yun is an accomplished inventor based in Burlingame, CA (US). He has made significant contributions to the field of immunology through his innovative work on oligonucleotide constructs. His research focuses on developing therapies that can enhance the immune response against various diseases.

Latest Patents

Theodore Yun holds a patent for "Oligonucleotide constructs and uses thereof." This patent describes oligo-deoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists. The patent outlines compositions that include these TLR9 agonists, methods for their production, and their application in treating immune diseases, disorders, or conditions such as viral infections and cancer.

Career Highlights

Yun is currently employed at Janssen Biopharma, Inc., where he continues to advance his research in immunotherapy. His work is pivotal in developing new treatment options that leverage the body's immune system to combat diseases.

Collaborations

Theodore Yun has collaborated with notable colleagues in his field, including Sergei M Gryaznov and Leonid Beigelman. These partnerships have contributed to the advancement of his research and the development of innovative therapies.

Conclusion

Theodore Yun's contributions to immunology through his patented innovations highlight the potential of oligonucleotide constructs in treating serious health conditions. His work at Janssen Biopharma, Inc. continues to pave the way for future advancements in immunotherapy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…